logo
Ozempic Reduces Desire to Binge Alcohol, Suggests Amazing New Study

Ozempic Reduces Desire to Binge Alcohol, Suggests Amazing New Study

Yahoo19-02-2025

People using semaglutide for diabetes or weight loss have also reported experiencing a reduced desire for alcohol.
A new study confirms there's likely something to the anecdotes, with a staggering 30 percent reduction in alcohol consumption per drinking day for those given the medication, compared to a 2 percent reduction with a placebo.
University of North Carolina psychiatrist Christian Hendershot and colleagues found weekly injections of semaglutide, better known as Ozempic or Wegovy, not only decreased consumption in those with symptoms of alcohol use disorder compared to those given a placebo, but reduced patient cravings too.
If this holds true, it could be life-changing for the almost 30 million people in the US with alcohol use disorder.
So Hendershot and team put semaglutide to the test in a phase 2 clinical trial. It involved 48 patients with an average age of around 40, who all met the diagnostic criteria for alcohol use disorder but weren't seeking treatment.
Each participant had a drinking history of more than 7 drinks a week for women, or 14 for men, over the last month. That includes two or more heavy drinking episodes, involving four or more drinks for women and five or more for men.
Over nine weeks, the participants received a dose of semaglutide or a placebo once a week. They were then asked to log their alcohol cravings and consumption levels during the trial.
While the number of overall drinking days didn't alter much over the course of the trial, by the second month almost 40 percent of those in the semaglutide group had no heavy drinking days compared to 20 percent in the placebo.
"Semaglutide significantly reduced alcohol craving and drinks per drinking day," Hendershot and team wrote in their paper.
The researchers also noted a reduction in smoking too, although this was in a very small subgroup of only seven people in the placebo group and six in the treatment group.
The patients involved in the trial had up to moderate levels of alcohol use disorder, so the results may not translate to those who are at the drinking levels where they start to seek treatment. But the results certainly support a case for further investigation.
"These data suggest the potential of semaglutide and similar drugs to fill an unmet need for the treatment of alcohol use disorder," says University of North Carolina endocrinologist Klara Klein.
"Larger and longer studies in broader populations are needed to fully understand the safety and efficacy in people with alcohol use disorder, but these initial findings are promising."
This isn't the only unexpected use for this oddly multitalented pharmaceutical. Studies in animals or humans have found semaglutide may also help those with osteoarthritis, fatty liver disease, dementia, kidney disease, and other addictions as well.
But as with all medications, it's important to remember changing our biochemistry can come with consequences. Possible side effects of semaglutide use so far range from nausea to shrinking heart muscles. We're still discovering the long-term impacts of this drug on human bodies.
This research was published in JAMA Psychiatry.
Going Gluten Free Could Come at a Cost to Your Nutrition And Your Pocket
A Global Oxygen Crisis Is Putting Millions of Lives at Risk
Doctor Realizes He's Having a Heart Attack While Treating Heart Attack Patient

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Study: Real-world results of GLP-1 drugs don't match trials
Study: Real-world results of GLP-1 drugs don't match trials

Yahoo

time2 hours ago

  • Yahoo

Study: Real-world results of GLP-1 drugs don't match trials

Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised by the drugs' clinical trials, a new study says. People taking such GLP-1 drugs lost just under 9% of their body weight on average after a year, researchers reported Tuesday in the journal Obesity. That's far less than the 15% to 21% body weight reduction promised by the clinical trials that led to the approval of Wegovy (semaglutide) and Zepbound (tirzepatide) for weight loss, researchers said. "Patients treated for obesity with semaglutide or trizepatide lost less weight on average in a regular clinical setting compared to what is observed in randomized clinical trial," lead investigator Hamlet Gasoyan said in a news release. He is a researcher at the Cleveland Clinic Center for Value-Based Care Research. People taking the drugs in real-world settings appear to be more likely to quit taking the meds, researchers said. They also might be prescribed lower dosages in clinical practice than were used in the drug trials. Glucagon-like peptide-1 (GLP-1) drugs mimic the GLP-1 hormone, which helps control insulin and blood sugar levels, decreases appetite and slows digestion of food. For this study, researchers tracked nearly 7,900 patients being treated by the Cleveland Clinic for severe obesity, of whom about 6,100 were prescribed semaglutide and the rest tirzepatide. Average body weight loss after a year was nearly 9% for the whole group, results show. But weight loss varied based on when a person stopped taking the drugs, researchers found. Average weight loss was under 4% for those who stopped treatment early, versus nearly 7% or those who stopped later on, the study says. Those who stayed on their medications lost an average 12% body weight. Results also show that more than 4 in 5 (81%) of patients were prescribed a low maintenance dose of their GLP-1 drug, and that made a difference as well. People who stayed on their meds and received high doses lost nearly 14% of their body weight with semaglutide and 18% with tirzepatide. "Our findings about the real-world use patterns of these medications and associated clinical outcomes could inform the decisions of health care providers and their patients on the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight reductions," Gasoyan said. Overall, patients had higher odds of losing 10% or more of their body weight after a year if they remained on their meds, were prescribed a high dosage, were taking tirzepatide rather than semaglutide, and were female, results show. The cost of the drugs and problems were insurance were a common reason for patients stopping GLP-1 treatment, along with side effects and medication shortages, researchers said. Staying on the GLP-1 meds particularly helped the nearly 17% of patients who had prediabetes, a condition in which elevated blood sugar levels increase a person's risk of developing Type 2 diabetes. About 68% of those who stuck with their treatment wound up with normal blood sugar levels, compared with 41% who stopped taking the drugs later in the study and 33% who stopped earlier. "Type 2 diabetes is one of the most common complications of obesity, so diabetes prevention is very important," Gasoyan said. "This study highlights that treatment discontinuation, especially early, negatively affects both weight and glycemic control outcomes." A follow-up study is in the works to better track why patients stop taking their GLP-1 drugs, researchers said. More information Harvard Medical School has more on GLP-1 drugs. Copyright © 2025 HealthDay. All rights reserved.

Lawmakers urge Trump administration to clamp down on illicit GLP-1 sales
Lawmakers urge Trump administration to clamp down on illicit GLP-1 sales

The Hill

time3 hours ago

  • The Hill

Lawmakers urge Trump administration to clamp down on illicit GLP-1 sales

A bipartisan group of congressional lawmakers is calling on the Trump administration to address the continued sale of illicit, compounded GLP-1 products, warning that consumers may be accessing these drugs without knowing the product could be fraudulent. North Carolina Reps. Brad Knott (R) and Deborah Ross (D) wrote to Food and Drug Administration (FDA) Commissioner Marty Makary, Homeland Security Secretary Kristi Noem and U.S. Attorney General Pam Bondi, imploring them to end the sale of 'counterfeit, research-grade and illegal copycats' of popular GLP-1 medications. When the commercial, branded versions of tirzepatide and semaglutide were declared to no longer be in shortage, compounding pharmacies were disallowed from continuing to sell compounded versions of those drugs. While telehealth companies have transitioned away from compounded versions, state officials have warned that 'copycat' drugs have proliferated in the months since the shortages ended. Earlier this year, the National Association of Attorneys General sent a letter to the FDA to warn that 'counterfeit GLP-1 drugs have infiltrated the U.S. supply chain from China, Turkey, India, and other foreign sources.' According to the attorneys general, online retailers sell the active ingredient for the GLP-1s under the claim that they're 'for research purposes only' or 'not for human consumption' while still marketing them to consumers on social media. The FDA issued a warning in April, telling consumers to not take counterfeit Ozempic. The drug's manufacturer, Novo Nordisk, had alerted the agency that several hundred units of counterfeit product had entered the U.S. supply chain. At the time, the FDA said it was aware of six adverse events associated with the counterfeit products. Though the FBI issued a public service warning soon after the letter from the attorneys general was sent, Knott and Ross said raising public awareness wasn't enough. 'FDA has received hundreds of reports of adverse events, even some resulting in the hospitalization and death of patients who used illicit GLP-1s,' they wrote. 'This is likely a significant underreporting of adverse events experienced by patients because federal law does not require state-licensed pharmacies that are not outsourcing facilities to submit adverse events to FDA.' The lawmakers asked that the Trump Cabinet members fully use 'the legal tools at your discretion' to further detect illicit and enforce U.S. drug standards. Sen. Thom Tillis (R-N.C.) sent his own letter to Cabinet members, calling for enhanced collaboration among agencies like FDA, U.S. Customs and Border Protection and the Justice Department in order to stop the counterfeit products from reaching the supply chain in the first place. The Hill has reached out to the agencies named in the letter for comment.

Can Mounjaro, Zepbound Help Lilly Maintain Dominance in Obesity Space?
Can Mounjaro, Zepbound Help Lilly Maintain Dominance in Obesity Space?

Yahoo

time4 hours ago

  • Yahoo

Can Mounjaro, Zepbound Help Lilly Maintain Dominance in Obesity Space?

Eli Lilly's LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both have witnessed rapid demand despite being on the market for less than three years. Mounjaro and Zepbound include the same compound tirzepatide, a dual GIP and GLP-1 receptor agonist. Mounjaro and Zepbound generated combined sales of $6.15 billion in the first quarter of 2025, accounting for around 48% of the company's total revenues. Both drugs enjoy increasing market share in the United States. Though sales of Mounjaro and Zepbound were below expectations in the second half of 2024, hurt by slower-than-expected growth and unfavorable channel dynamics, their sales picked up in the first quarter of 2025, driven by launches of the drugs in new international markets and improved supply from ramped-up production. Since 2020, Lilly has committed more than $50 billion to manufacturing capacity for its drugs, mainly Zepbound and Mounjaro, in the United States and Europe. We believe that increased uptake in outside U.S. markets and deeper penetration into the U.S. market will continue to drive Mounjaro and Zepbound's growth in future quarters. Our model estimates combined Mounjaro and Zepbound sales of $48.2 billion by 2027. Approvals for new indications can also drive sales of Mounjaro and Zepbound higher. In late December, the FDA approved Zepbound for its second indication, moderate-to-severe obstructive sleep apnea in adults with obesity. In addition, LLY filed tirzepatide for heart failure, which further expands the opportunity for the candidate. It also expects to announce data from a cardiovascular outcome study on tirzepatide this year. The obesity market is heating up and is expected to expand to $100 billion by 2030, according to data from Goldman Sachs. Lilly and Novo Nordisk NVO presently dominate the market. Mounjaro and Zepbound face strong competition from Novo Nordisk's semaglutide medicines, Ozempic for diabetes and Wegovy for obesity. Several companies like Amgen AMGN and Viking Therapeutics VKTX are also making rapid progress in the development of GLP-1-based candidates in their clinical pipeline. Amgen has begun a broad phase III program on its dual GIPR/GLP-1 receptor agonist, MariTide, across obesity, obesity-related conditions and type II diabetes, with the first two phase III studies initiated in March. Viking Therapeutics' dual GIPR/GLP-1 receptor agonist, VK2735, is being developed both as oral and subcutaneous formulations for the treatment of obesity. Phase III studies with the subcutaneous formulation of VK2735 are on track to begin this year. Others like Roche, Merck and AbbVie are also looking to enter the obesity space by in-licensing obesity candidates from smaller biotechs, which could threaten Novo Nordisk and Eli Lilly's dominance in the market. Lilly's stock has risen 5% so far this year compared with the industry's increase of 0.6%. Image Source: Zacks Investment Research From a valuation standpoint, Lilly's stock is expensive. Going by the price/earnings ratio, the company's shares currently trade at 31.21 forward earnings, higher than 15.17 for the industry. However, the stock is trading below its 5-year mean of 34.54. Image Source: Zacks Investment Research Estimates for Lilly's 2025 earnings have declined from $23.49 to $21.95 per share in the past 60 days, while those for 2026 have declined from $31.28 to $30.91 over the same timeframe. Image Source: Zacks Investment Research Lilly has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report Viking Therapeutics, Inc. (VKTX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store